WILLIAM FULLER: Open Payments
NPI 1326440488 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$745 in 36 payments from 14 companies in 2025. Trend: 2023 $502 · 2024 $739 · 2025 $745
Food & beverage: $745
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 6 | $122 |
| Novartis Pharmaceuticals Corporation | 5 | $112 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $107 |
| Alnylam Pharmaceuticals Inc. | 4 | $87 |
| Amgen Inc. | 4 | $60 |
| Medtronic, Inc. | 2 | $52 |
| Boston Scientific Corporation | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Abbott Laboratories | 1 | $24 |
Products named: ELIQUIS, LEQVIO, JARDIANCE, AMVUTTRA, REPATHA, FARXIGA, LINQ II, CAMZYOS.
Industry payments across CA — which companies pay providers there.
